Develops injectable hyaluronic acid products for osteoarthritis pain relief.
Jun 2026Revenue $121M/yrExpenses $126M/yr
No trend
Figures by year
When will Anika Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $121M and expenses $126M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $113M | $124M | −$11.1M |
| Dec 2024 | $120M | $125M | −$5.10M |
| Dec 2023 | $121M | $120M | $844K |
| Dec 2022 | $114M | $110M | $3.67M |
| Dec 2021 | $148M | $145M | $2.62M |
| Dec 2020 | $130M | $159M | −$28.3M |
| Dec 2019 | $115M | $80.4M | $34.2M |
| Dec 2018 | $106M | $83.8M | $21.7M |
| Dec 2017 | $113M | $67.7M | $45.7M |
| Dec 2016 | $103M | $52.8M | $50.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.